î
îž
î
Biogen Inc
BIIB181.940USD
-0.020-0.01%
āļāļīāļÂ 11/26, 16:00ïžETïžāļĢāļēāļāļēāļĨāđāļēāļāđāļē 15 āļāļēāļāļĩ
26.69BāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
16.59P/E TTM
î
āļĢāļēāļĒāļĨāļ°āđāļāļĩāļĒāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļāļ Biogen Inc āļāļĢāļīāļĐāļąāļ
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
āļāđāļāļĄāļđāļĨ Biogen Inc
îāļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļBIIB
āļāļ·āđāļāļāļĢāļīāļĐāļąāļBiogen Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļSep 17, 1991
āļāļĩāļāļĩāđāļMr. Christopher A. (Chris) Viehbacher
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ7605
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļSep 17
āļāļĩāđāļāļĒāļđāđ225 Binney Street
āđāļĄāļ·āļāļCAMBRIDGE
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ Global Select Consolidated
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02142
āđāļāļĢāļĻāļąāļāļāđ17814642000
āđāļ§āđāļāđāļāļāđhttps://www.biogen.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļBIIB
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļSep 17, 1991
āļāļĩāļāļĩāđāļMr. Christopher A. (Chris) Viehbacher
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļāļāļāļ Biogen Inc
îāļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+55.38%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+12.13%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+1.19%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+23.75%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-16.53%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
8.42K
+39.19%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
5.77K
-8.22%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
5.47K
+76.33%
Ms. Susan Langer
Ms. Susan Langer
Independent Director
Independent Director
3.79K
+166.90%
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+55.38%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+12.13%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+1.19%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+23.75%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-16.53%
āļŠāļąāļāļŠāđāļ§āļāļāļāļāļĢāļēāļĒāđāļāđ
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļĢāđāļāļĩāđ 6 āļ.āļ.
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļĢāđāļāļĩāđ 6 āļ.āļ.
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
MS product revenues-TYSABRI
839.80M
31.74%
Spinal Muscular Atrophy-SPINRAZA
543.00M
20.53%
MS product revenues-Fumarate
405.90M
15.34%
MS product revenues-Interferon
246.70M
9.33%
Biosimilar product revenues-BENEPALI
112.10M
4.24%
āļāļ·āđāļ āđ
498.00M
18.82%
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
United States
1.38B
52.21%
Rest of World
937.60M
35.44%
United states-Revenues from anti-CD20 therapeutic
467.30M
17.66%
Rest of World-Other revenues
244.60M
9.25%
āļāļēāļĄāļāļļāļĢāļāļīāļ
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļ
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
MS product revenues-TYSABRI
839.80M
31.74%
Spinal Muscular Atrophy-SPINRAZA
543.00M
20.53%
MS product revenues-Fumarate
405.90M
15.34%
MS product revenues-Interferon
246.70M
9.33%
Biosimilar product revenues-BENEPALI
112.10M
4.24%
āļāļ·āđāļ āđ
498.00M
18.82%
āļŠāļāļīāļāļīāļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 16 āļ.āļĒ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 16 āļ.āļĒ.
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
āļāļ·āđāļ āđ
64.59%
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
āļāļ·āđāļ āđ
64.59%
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Investment Advisor
52.44%
Investment Advisor/Hedge Fund
26.19%
Hedge Fund
8.03%
Pension Fund
2.94%
Research Firm
2.45%
Sovereign Wealth Fund
1.59%
Bank and Trust
1.59%
Individual Investor
0.17%
Family Office
0.15%
āļāļ·āđāļ āđ
4.45%
āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļ
îāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļļāļāļāļĩāđ 1 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļļāļāļāļĩāđ 1 āļ.āļ.
āļāđāļ§āļāđāļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļāļēāļ
āļāļģāļāļ§āļāļŠāļāļēāļāļąāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
2025Q3
2020
136.90M
93.32%
-6.47M
2025Q2
2075
135.74M
92.58%
-12.69M
2025Q1
2149
136.82M
93.38%
-11.44M
2024Q4
2130
138.58M
94.69%
-5.19M
2024Q3
2109
135.95M
93.33%
-6.54M
2024Q2
2116
135.72M
93.21%
-7.14M
2024Q1
2121
136.44M
93.87%
-5.95M
2023Q4
2151
135.61M
93.59%
-2.07M
2023Q3
2177
132.42M
91.43%
-7.53M
2023Q2
2240
133.77M
92.42%
-4.86M
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļīāļāļāļĢāļĢāļĄāļāļđāđāļāļ·āļāļŦāļļāđāļ
îāļāļ·āđāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
āđāļāļĨāļĩāđāļĒāļ%
āļ§āļąāļāļāļĩāđ
The Vanguard Group, Inc.
17.21M
11.74%
+255.44K
+1.51%
Jun 30, 2025
PRIMECAP Management Company
15.80M
10.78%
-141.14K
-0.89%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.19M
5.59%
-504.36K
-5.80%
Jun 30, 2025
State Street Investment Management (US)
7.47M
5.09%
+71.90K
+0.97%
Jun 30, 2025
Wellington Management Company, LLP
4.80M
3.27%
+125.98K
+2.70%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.92M
2.67%
+71.29K
+1.85%
Jun 30, 2025
Point72 Asset Management, L.P.
3.83M
2.61%
+3.42M
+840.86%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
3.00M
2.05%
-10.62K
-0.35%
Aug 31, 2025
Norges Bank Investment Management (NBIM)
2.26M
1.54%
-61.02K
-2.62%
Jun 30, 2025
Invesco Capital Management LLC
2.04M
1.39%
+32.06K
+1.59%
Jun 30, 2025
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ETF āļāļĩāđāđāļāļĩāđāļĒāļ§āļāđāļāļ
îāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļĪāļŦāļąāļŠāļāļĩāđ 6 āļ.āļĒ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļĪāļŦāļąāļŠāļāļĩāđ 6 āļ.āļĒ.
āļāļ·āđāļ
āļŠāļąāļāļŠāđāļ§āļ
Invesco Biotechnology & Genome ETF
5.03%
iShares Neuroscience and Healthcare ETF
4.13%
First Trust NASDAQ Pharmaceuticals ETF
3.82%
VanEck Biotech ETF
3.33%
First Trust NYSE Arca Biotechnology Index Fund
3.24%
Invesco Pharmaceuticals ETF
2.74%
First Trust Health Care Alphadex Fund
2.36%
Global X US Cash Flow Kings 100 ETF
2.26%
ProShares Ultra Nasdaq Biotechnology
2.12%
Invesco Nasdaq Biotechnology ETF
2.08%
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Invesco Biotechnology & Genome ETF
āļŠāļąāļāļŠāđāļ§āļ5.03%
iShares Neuroscience and Healthcare ETF
āļŠāļąāļāļŠāđāļ§āļ4.13%
First Trust NASDAQ Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ3.82%
VanEck Biotech ETF
āļŠāļąāļāļŠāđāļ§āļ3.33%
First Trust NYSE Arca Biotechnology Index Fund
āļŠāļąāļāļŠāđāļ§āļ3.24%
Invesco Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ2.74%
First Trust Health Care Alphadex Fund
āļŠāļąāļāļŠāđāļ§āļ2.36%
Global X US Cash Flow Kings 100 ETF
āļŠāļąāļāļŠāđāļ§āļ2.26%
ProShares Ultra Nasdaq Biotechnology
āļŠāļąāļāļŠāđāļ§āļ2.12%
Invesco Nasdaq Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ2.08%
āđāļāļīāļāļāļąāļāļāļĨ
îāļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
āļ§āļąāļāļāļĩāđ
āđāļāļīāļāļāļąāļāļāļĨ
āļ§āļąāļāļāļĩāđāļāļąāļāļāļķāļ
āļ§āļąāļāļāļĩāđāļāļģāļĢāļ°āđāļāļīāļ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļāļēāļĢāđāļāđāļāļŦāļļāđāļ
îāļ§āļąāļāļāļĩāđ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļ§āļąāļāļāļĩāđ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļāļģāļāļēāļĄāļāļĩāđāļāļāļāđāļāļĒ
āđāļāļĢāļāļ·āļāļāļđāđāļāļ·āļāļŦāļļāđāļāļŦāđāļēāļāļąāļāļāļąāļāđāļĢāļāļāļāļ Biogen Inc?
îāļāļđāđāļāļ·āļāļŦāļļāđāļāļŦāđāļēāļāļąāļāļāļąāļāđāļĢāļāļāļāļ Biogen Inc āđāļāđāđāļāđ:
The Vanguard Group, Inc. āļāļ·āļāļāļĢāļāļāļŦāļļāđāļāļāļģāļāļ§āļ 17.21M āļŦāļļāđāļ āļāļīāļāđāļāđāļ 11.74% āļāļāļāļŦāļļāđāļāļāļąāđāļāļŦāļĄāļ
PRIMECAP Management Company āļāļ·āļāļāļĢāļāļāļŦāļļāđāļāļāļģāļāļ§āļ 15.80M āļŦāļļāđāļ āļāļīāļāđāļāđāļ 10.78% āļāļāļāļŦāļļāđāļāļāļąāđāļāļŦāļĄāļ
BlackRock Institutional Trust Company, N.A. āļāļ·āļāļāļĢāļāļāļŦāļļāđāļāļāļģāļāļ§āļ 8.19M āļŦāļļāđāļ āļāļīāļāđāļāđāļ 5.59% āļāļāļāļŦāļļāđāļāļāļąāđāļāļŦāļĄāļ
State Street Investment Management (US) āļāļ·āļāļāļĢāļāļāļŦāļļāđāļāļāļģāļāļ§āļ 7.47M āļŦāļļāđāļ āļāļīāļāđāļāđāļ 5.09% āļāļāļāļŦāļļāđāļāļāļąāđāļāļŦāļĄāļ
Wellington Management Company, LLP āļāļ·āļāļāļĢāļāļāļŦāļļāđāļāļāļģāļāļ§āļ 4.80M āļŦāļļāđāļ āļāļīāļāđāļāđāļ 3.27% āļāļāļāļŦāļļāđāļāļāļąāđāļāļŦāļĄāļ
The Vanguard Group, Inc. āļāļ·āļāļāļĢāļāļāļŦāļļāđāļāļāļģāļāļ§āļ 17.21M āļŦāļļāđāļ āļāļīāļāđāļāđāļ 11.74% āļāļāļāļŦāļļāđāļāļāļąāđāļāļŦāļĄāļ
PRIMECAP Management Company āļāļ·āļāļāļĢāļāļāļŦāļļāđāļāļāļģāļāļ§āļ 15.80M āļŦāļļāđāļ āļāļīāļāđāļāđāļ 10.78% āļāļāļāļŦāļļāđāļāļāļąāđāļāļŦāļĄāļ
BlackRock Institutional Trust Company, N.A. āļāļ·āļāļāļĢāļāļāļŦāļļāđāļāļāļģāļāļ§āļ 8.19M āļŦāļļāđāļ āļāļīāļāđāļāđāļ 5.59% āļāļāļāļŦāļļāđāļāļāļąāđāļāļŦāļĄāļ
State Street Investment Management (US) āļāļ·āļāļāļĢāļāļāļŦāļļāđāļāļāļģāļāļ§āļ 7.47M āļŦāļļāđāļ āļāļīāļāđāļāđāļ 5.09% āļāļāļāļŦāļļāđāļāļāļąāđāļāļŦāļĄāļ
Wellington Management Company, LLP āļāļ·āļāļāļĢāļāļāļŦāļļāđāļāļāļģāļāļ§āļ 4.80M āļŦāļļāđāļ āļāļīāļāđāļāđāļ 3.27% āļāļāļāļŦāļļāđāļāļāļąāđāļāļŦāļĄāļ
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļāļŠāļēāļĄāļāļąāļāļāļąāļāđāļĢāļāļāļāļ Biogen Inc āļāļ·āļāļāļ°āđāļĢ?
îāļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļāļŠāļēāļĄāļāļąāļāļāļąāļāđāļĢāļāļāļāļ Biogen Inc āđāļāđāđāļāđ
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
āļĄāļĩāļāļĩāđāļŠāļāļēāļāļąāļāļāļĩāđāļāļ·āļāļŦāļļāđāļāļāļāļ Biogen Inc (BIIB)?
îāļ āļ§āļąāļāļāļĩāđ 2025Q3 āļĄāļĩāļŠāļāļēāļāļąāļāļāļģāļāļ§āļ 2020 āđāļŦāđāļāļāļĩāđāļāļ·āļāļŦāļļāđāļāļāļāļ Biogen Inc āđāļāļĒāļĄāļĩāļĄāļđāļĨāļāđāļēāļĢāļ§āļĄāļāļĢāļ°āļĄāļēāļ 136.90M āļāļīāļāđāļāđāļ 93.32% āļāļāļāļŦāļļāđāļāļāļąāđāļāļŦāļĄāļ āđāļĄāļ·āđāļāđāļāļĩāļĒāļāļāļąāļāļ§āļąāļāļāļĩāđ 2025Q2 āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļāđāļāđāđāļāļīāđāļĄāļāļķāđāļ 0.73%
āđāļŦāļĨāđāļāļĢāļēāļĒāđāļāđāļŦāļĨāļąāļāļāļāļ Biogen Inc āļāļ·āļāļāļ°āđāļĢ?
îāđāļĄāļ·āđāļāļ§āļąāļāļāļĩāđ FY2025Q2 āļāļļāļĢāļāļīāļāļāđāļēāļ MS product revenues-TYSABRI āļŠāļĢāđāļēāļāļĢāļēāļĒāđāļāđāļŠāļđāļāļŠāļļāļāđāļŦāđāļāļąāļ Biogen Inc āļāļīāļāđāļāđāļāļĄāļđāļĨāļāđāļē 839.80M āđāļĨāļ°āļāļīāļāđāļāđāļ 31.74% āļāļāļāļĢāļēāļĒāđāļāđāļĢāļ§āļĄ
